Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 2 > 100199
Next Article Previous Article
LETTER   Open Access     Cite

The landscape of top 10 global innovative drug targets 2015-2024

  • 1.

    Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China

  • 2.

    Department of Biochemistry and Molecular Biology, Eberly College of Science, The Pennsylvania State University, University Park, PA 16802, USA

  • 3.

    Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China

More Information
  • Corresponding author: pengfeixu@whu.edu.cn
  • Received Date:  August 06, 2025
    Accepted Date:  February 05, 2026
    Published Online:  February 06, 2026
The Innovation Medicine  4(2),  https://doi.org/10.59717/j.xinn-med.2026.100199  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Ge Q., Xu L., DiMasi J.A., et al. (2023). Impact of regulatory system changes on the availability of innovative drugs in China. Nat. Rev. Drug Discov. 22:344−345. DOI:10.1038/d41573-023-00058-0

    View in Article CrossRef Google Scholar

    [2] Sun D., Gao W., Hu H., et al. (2022). Why 90% of clinical drug development fails and how to improve it. Acta Pharm. Sin. B 12:3049−3062. DOI:10.1016/j.apsb.2022.02.002

    View in Article CrossRef Google Scholar

    [3] Marron T.U., Luke J.J., Hoffner B., et al. (2025). A SITC vision: Adapting clinical trials to accelerate drug development in cancer immunotherapy. J. Immunother. Cancer 13:e010760. DOI:10.1136/jitc-2024-010760

    View in Article CrossRef Google Scholar

    [4] Chang C.A., Emberley E., D'Souza A.L., et al. (2024). ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies. Blood 144:757−770. DOI:10.1182/blood.2024023849

    View in Article CrossRef Google Scholar

    [5] Yu B., Jiang T. and Liu D. (2020). BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol. 13:125. DOI:10.1186/s13045-020-00962-7

    View in Article CrossRef Google Scholar

    [6] Klein C., Brinkmann U., Reichert J.M., et al. (2024). The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23:301−319. DOI:10.1038/s41573-024-00896-6

    View in Article CrossRef Google Scholar

    [7] Liu X., Zhao J., Guo X., et al. (2023). CD20 × CD3 bispecific antibodies for lymphoma therapy: Latest updates from ASCO 2023 annual meeting. J. Hematol. Oncol. 16:90. DOI:10.1186/s13045-023-01488-4

    View in Article CrossRef Google Scholar

    [8] Shitara K., Bang Y.J., Iwasa S., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382:2419−2430. DOI:10.1056/NEJMoa2004413

    View in Article CrossRef Google Scholar

    [9] Napolitano S., Martini G., Ciardiello D., et al. (2024). Targeting the EGFR signalling pathway in metastatic colorectal cancer. Lancet Gastroenterol. Hepatol. 9:664−676. DOI:10.1016/s2468-1253(23)00479-x

    View in Article CrossRef Google Scholar

    [10] Morris M.J., Castellano D., Herrmann K., et al. (2024). (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. Lancet 404:1227−1239. DOI:10.1016/s0140-6736(24)01653-2

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Tan C., Wang X., Ding D., et al. (2026). The landscape of top 10 global innovative drug targets 2015-2024. The Innovation Medicine 4:100199. https://doi.org/10.59717/j.xinn-med.2026.100199
    Tan C., Wang X., Ding D., et al. (2026). The landscape of top 10 global innovative drug targets 2015-2024. The Innovation Medicine 4:100199. https://doi.org/10.59717/j.xinn-med.2026.100199

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(1845) PDF downloads(2224)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.